UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Act of 1934
Date of Report (Date of earliest event reported): January 7, 2019
MAGENTA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-38541 | 81-0724163 | ||
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification Number) |
100 Technology Square
Cambridge, Massachusetts 02139
(857)242-0170
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Check the appropriate box below if theForm 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant toRule 14a-12 under the Exchange Act (17 CFR240.14a-12) |
☐ | Pre-commencement communications pursuant toRule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b)) |
☐ | Pre-commencement communications pursuant toRule 13e-4(c) under the Exchange Act (17 CFR240.13d-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule12b-2 of the Securities Exchange Act of 1934(§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01. | Regulation FD Disclosure. |
The following information and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
Jason Gardner, the Chief Executive Officer of Magenta Therapeutics, Inc. (the “Company”), will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on January 9, 2019 at 9:30 a.m. PST. The presentation will be accessible by a live audio webcast through the Company’s website at www.magentatx.com and a copy of the presentation slide deck is being furnished as Exhibit 99.1 to this Current Report on Form8-K.
Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
The following exhibit relating to Item 7.01 shall be deemed furnished, and not filed:
Exhibit | Description | |
99.1 | Copy of Magenta Therapeutics, Inc. slide presentation dated January 2019. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MAGENTA THERAPEUTICS, INC. | ||
Date: | January 7, 2019 | |
By: | /s/ Jason Ryan | |
Title: | Chief Operating and Financial Officer |
3